In line with our in vitro results, ACCN1 (ASIC2) was downregulated in all types of glioma samples as compared to the non-tumour samples used as control (P < 0.001, two-sided t-test; Fig. 10a). This evidence concerns the gene ASIC2 and central nervous system cancer.